No abstract

During the experiment, the modeling of endothelial dysfunction of male rats was performed by intraperitoneal administration of L-NAME at a dose of 25 mg/kg for 7 days, and the same of female rats was performed by bilateral ovarioectomy and further intraperitoneal administration of L-NAME at a dose of 25 mg/kg for 7. The deficiency of nitric oxide as a result of the NO-synthase blockade was accompanied by the impairment of the endotheliumdependent and independent vasodilatation estimated in the pharmacological tests, which was expressed in the increasing coefficient of endothelial dysfunction. As a result of the research it was discovered that the combined application of thioctic acid at a dose of 50 mg/kg/day with antioxidant features and rosuvastatin at a dose of 0.85 mg/kg/day, which is a lipid-lowering drug, has endothelioprotective effect on the models of L-NAME-induced and hypoestrogen-LNAME-induced deficiency of nitric oxide, which is expressed in prevalence of endotheliumdependent relaxations of vessels and decreasing coefficient of endothelial dysfunction, as well as prevention of increase in nitric oxide production.

No abstract

Pyrazine derivatives Pyrazine derivatives R 0550Azacycloalkanes. Part 34. Synthesis and Antiarrhythmic Activity of 2-(2'-R-2'-Hydroxyethyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazines. -A variety of novel title hydroxyethyl-substituted tetrahydropyrrolopyrazines (III) are prepared as demonstrated for derivative (IIIa) and isolated as fumarate salts. Among them, derivatives (IIIa) and (IIIc) possess the highest antiarrhythmic activity. -(LIKHOSHERSTOV, A. M.; FILIPPOVA, O. V.; PERESADA*, V. P.; KRYZHANOVSKII, S. A.; VITITNOVA, M. B.; KAVERINA, N. V.; REZNIKOV, K. M.; Khim.-Farm.

pyrroles. -Among the title compounds (V), (VII), (VIII) and (IX), prepared by condensation of mesidine (II) with furfural derivative (I) followed by reductive amination and N-acylation-reduction, the lowest toxicity is observed for N-non-acylated derivative (V). It possesses antiarrhythmic activity comparable to therapeutically applied substances like propranolol or novocainamide. -(LIKHOSHERSTOV, A. M.; FILIPPOVA, O. V.; PERESADA*, V. P.; KRYZHANOVSKII, S. A.; VITITNOVA, M. B.; KAVERINA, N. V.; REZNIKOV, K. M.; Khim.-Farm. Zh. 37 (2003) 10, 8-11; Nauchno-issled. inst. farmakol. Ross. Akad. med. nauk, Moskva 125315, Russia; Russ.) -Mischke 10-114